Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 5, pp 1116–1130 | Cite as

Community pharmacists’ attitudes and opinions towards supplying clozapine

  • Yuh-Lin Gan
  • Claire L. O’ReillyEmail author
Research Article
  • 129 Downloads

Abstract

Background Clozapine is very effective for treatment-resistant schizophrenia, but its use has been limited due to the risk of agranulocytosis. From July 2015, clozapine has been accessible from Australian community pharmacies following regulatory changes, but pharmacists’ attitudes towards these changes remain unknown. Objective To explore pharmacists’ perspectives and experiences in supplying clozapine. Setting Australian community pharmacists. Methods A cross-sectional study with a mixed methods approach involving two phases. An online survey containing Likert-type and open-response questions was distributed to community pharmacists (n = 134) via ClopineCentral™ (clozapine monitoring system). Participants were then invited to participate in semi-structured telephone interviews (n = 12) regarding clozapine supply. Quantitative data were statistically analysed, while qualitative responses were thematically content-analysed. Main outcome measures Pharmacists’ responses to surveys and interviews. Results Community pharmacists were supportive towards supplying clozapine as it increased access for consumers. Better patient-pharmacist relationships and holistic care approach were identified to benefit both consumers and pharmacists. Pharmacists reported to be confident (89.6%), have adequate support (73.1%), knowledge (86.6%) and skills (93.3%) in dispensing clozapine. Training and support received facilitated pharmacists’ roles, whereas administrative issues, especially in obtaining valid haematology results, posed challenges. Educational and technical improvements were suggested to improve service provision. Conclusion Community pharmacists welcomed the regulatory changes positively and were confident in supporting consumers taking clozapine. Despite challenges present, benefits and facilitators identified supported the feasibility of this service in community pharmacies. Future research should explore other aspects of clozapine supply, such as attitudes of other stakeholders, to improve current supply systems.

Keywords

Australia Clozapine Community pharmacy Pharmacy services Schizophrenia 

Notes

Acknowledgements

The authors wish to thank ClopineCentral™ and Hospira for assisting in survey distribution, and all community pharmacists who participated in this study.

Conflicts of interest

All authors declare that they have no conflicts of interest.

Funding

None.

Supplementary material

11096_2018_676_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–92.CrossRefGoogle Scholar
  2. 2.
    Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. Hoboken: Wiley; 2015. ISBN 9781118754573.Google Scholar
  3. 3.
    Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–72.CrossRefGoogle Scholar
  4. 4.
    Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14(1):102.CrossRefGoogle Scholar
  5. 5.
    Fakra E, Azorin J-M. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother. 2012;13(13):1923–35.CrossRefGoogle Scholar
  6. 6.
    Alvir JMJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry. 1994;55(Suppl B):137–8.PubMedGoogle Scholar
  7. 7.
    Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51.CrossRefGoogle Scholar
  8. 8.
    Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, et al. Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf. 2016;15(9):1193–203.CrossRefGoogle Scholar
  9. 9.
    Australian Government Department of Health. Pharmaceutical benefits scheme (PBS): new options for clozapine maintenance supply. Canberra: Australian Government Canberra. 2015. http://www.pbs.gov.au/general/changes-to-certain-s100-programs/faqs-hsd-ca-clozapine-25-june-2015.pdf. Accessed 28 Apr 2018.
  10. 10.
    Winckel K, Siskind D, Hollingworth S, Robinson G, Mitchell S, Varghese D, et al. Clozapine in the community: improved access or risky free-for-all? Aust N Z J Psychiatry. 2015;49(10):863–5.CrossRefGoogle Scholar
  11. 11.
    Crawford MJ, Jayakumar S, Lemmey SJ, Zalewska K, Patel MX, Cooper SJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry. 2014;205(6):473–7.CrossRefGoogle Scholar
  12. 12.
    Knowles SA, McMillan SS, Murphy K, Wheeler A. Providing clozapine in community pharmacy. Aust Pharm. 2015;35(1):56–9.Google Scholar
  13. 13.
    Ally B, Ally M. Clozapine in the community. Australas J Pharm. 2015;96(1145):66–71.Google Scholar
  14. 14.
    O’Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Soc Adm Pharm. 2015;11(3):e101–9.CrossRefGoogle Scholar
  15. 15.
    Jorm AF, Oh E. Desire for social distance from people with mental disorders. Aust N Z J Psychiatry. 2009;43(3):183–200.CrossRefGoogle Scholar
  16. 16.
    Cates ME, Burton AR, Woolley TW. Attitudes of pharmacists toward mental illness and providing pharmaceutical care to the mentally ill. Ann Pharmacother. 2005;39(9):1450–5.CrossRefGoogle Scholar
  17. 17.
    IBM Corp. IBM SPSS statistics for windows. 22.0th ed. Armonk, NY: IBM Corp.; 2013.Google Scholar
  18. 18.
    Pharmaceutical Society of Australia. Guidelines and standards for pharmacists: dose administration aids services. 2007. http://www.psa.org.au/downloads/community-pharmacy-agreements/dose-administration-aids/dose-administration-service-guidelines.pdf. Accessed 28 Apr 2018.
  19. 19.
    Pharmaceutical Society of Australia. Guidelines for pharmacists providing staged supply services. 2017. http://www.psa.org.au/wp-content/uploads/5366-PSA-Staged-Supply-guidelines-FINAL_WEB.pdf. Accessed 28 Apr 2018.
  20. 20.
    Knowles SA, McMillan SS, Wheeler AJ. Consumer access to clozapine in Australia: how does this compare to New Zealand and the United Kingdom? Pharm Pract. 2016;14(2):722.CrossRefGoogle Scholar
  21. 21.
    Hattingh HL, Emmerton L, Tin PNC, Green C. Utilization of community pharmacy space to enhance privacy: a qualitative study. Health Expect. 2016;19(5):1098–110.CrossRefGoogle Scholar
  22. 22.
    Hattingh HL, Knox K, Fejzic J, McConnell D, Fowler JL, Mey A, et al. Privacy and confidentiality: perspectives of mental health consumers and carers in pharmacy settings. Int J Pharm Pract. 2015;23(1):52–60.CrossRefGoogle Scholar
  23. 23.
    Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–18.CrossRefGoogle Scholar
  24. 24.
    Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. 2008;20(12):600–7.CrossRefGoogle Scholar
  25. 25.
    Mey A, Knox K, Kelly F, Davey AK, Fowler J, Hattingh L, et al. Trust and safe spaces: mental health consumers’ and carers’ relationships with community pharmacy staff. The Patient. 2013;6(4):281–9.CrossRefGoogle Scholar
  26. 26.
    Knox K, Kelly F, Mey A, Hattingh L, Fowler JL, Wheeler AJ. Australian mental health consumers’ and carers’ experiences of community pharmacy service. Health Expect. 2015;18(6):2107–20.CrossRefGoogle Scholar
  27. 27.
    Black E, Murphy AL, Gardner DM. Community pharmacist services for people with mental illnesses: preferences, satisfaction, and stigma. Psychiatr Serv. 2009;60(8):1123–7.CrossRefGoogle Scholar
  28. 28.
    Bell JS, Rosen A, Aslani P, Whitehead P, Chen TF. Developing the role of pharmacists as members of community mental health teams: perspectives of pharmacists and mental health professionals. Res Soc Adm Pharm. 2007;3(4):392–409.CrossRefGoogle Scholar
  29. 29.
    Vanderbilt AA, Dail MD, Jaberi P. Reducing health disparities in underserved communities via interprofessional collaboration across health care professions. J Multidiscip Healthc. 2015;8:205–8.CrossRefGoogle Scholar
  30. 30.
    Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157(6):975–81.CrossRefGoogle Scholar
  31. 31.
    Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21(11):1133–7.CrossRefGoogle Scholar
  32. 32.
    De las Cuevas C, Penate W, de Rivera L. Psychiatric patients’ preferences and experiences in clinical decision-making: examining concordance and correlates of patients’ preferences. Patient Educ Couns. 2014;96(2):222–8.CrossRefGoogle Scholar
  33. 33.
    Paton C, Esop R. Patients’ perceptions of their involvement in decision making about antipsychotic drug choice as outlined in the NICE guidance on the use of atypical antipsychotics in schizophrenia. J Ment Health. 2005;14(3):305–10.CrossRefGoogle Scholar
  34. 34.
    Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965–71.CrossRefGoogle Scholar
  35. 35.
    Murphy AL, Phelan H, Haslam S, Martin-Misener R, Kutcher SP, Gardner DM. Community pharmacists’ experiences in mental illness and addictions care: a qualitative study. Subst Abuse Treat Prev Policy. 2016;11(1):6.CrossRefGoogle Scholar
  36. 36.
    Rubio-Valera M, Chen TF, O’Reilly CL. New roles for pharmacists in community mental health care: a narrative review. Int J Environ Res Public Health. 2014;11:10967–90.CrossRefGoogle Scholar
  37. 37.
    Morral K, Morral J. A survey of community pharmacists’ attitudes towards mental illness. J Public Ment Health. 2016;15(2):93–102.CrossRefGoogle Scholar
  38. 38.
    Nordt C, Rössler W, Lauber C. Attitudes of mental health professionals toward people with schizophrenia and major depression. Schizophr Bull. 2006;32(4):709–14.CrossRefGoogle Scholar
  39. 39.
    Wheeler A, Mey A, Kelly F, Hattingh L, Davey AK. Education and training for community pharmacists in mental health practice: how to equip this workforce for the future. J Ment Health Train Educ Pract. 2014;9(3):133–44.CrossRefGoogle Scholar
  40. 40.
    Thornicroft G, Mehta N, Clement S, Evans-Lacko S, Doherty M, Rose D, et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. The Lancet. 2016;387(10023):1123–32.CrossRefGoogle Scholar
  41. 41.
    Corrigan PW, Morris SB, Michaels PJ, Rafacz JD, Rüsch N. Challenging the public stigma of mental illness: a meta-analysis of outcome studies. Psychiatr Serv. 2012;63(10):963–73.CrossRefGoogle Scholar
  42. 42.
    Bjorksten CE, Berry S. Impact of altered administrative processes for clozapine supply in a large-scale Australian mental health shared-care program. J Pharm Pract Res. 2015;45(2):193–7.CrossRefGoogle Scholar
  43. 43.
    Herist KN, Perri M, Rollins B. Financial analysis in pharmacy practice (pharmacy business administration). London: Pharmaceutical Press; 2011. ISBN 9780853698975.Google Scholar
  44. 44.
    New Zealand Ministry of Health. Community pharmacy services agreement. Ministry of Health NZ, Wellington. 2012. https://tas.health.nz/assets/Publications/Pharmacy-Documents/The-Agreement/Community-Pharmacy-Services-Agreement-generic-version.pdf. Accessed 28 Apr 2018.
  45. 45.
    Zou H, Li Z, Arthur D, Wang H. Self-management in Chinese people with schizophrenia and their caregivers: a qualitative study on facilitators and barriers. Int J Ment Health Nurs. 2014;23(4):355–63.CrossRefGoogle Scholar
  46. 46.
    Kim E, Gupta S, Bolge S, Chen CC, Whitehead R, Bates JA. Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. J Med Econ. 2010;13(2):185–92.CrossRefGoogle Scholar
  47. 47.
    Crump K, Boo G, Liew FS, Olivier T, So C, Sung JY, et al. New Zealand community pharmacists’ views of their roles in meeting medicine-related needs for people with mental illness. Res Soc Adm Pharm. 2011;7(2):122–33.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The University of Sydney School of Pharmacy, Faculty of Medicine and Health, Pharmacy and Bank Building A15The University of SydneySydneyAustralia

Personalised recommendations